STATESVILLE, N.C., Sept. 8, 2022 /PRNewswire/ — Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first quarter ended July 31, 2022.
Fiscal Year 2023 First Quarter Results:
Sales during the first quarter of fiscal year 2023 were $50,123,000, an increase of 26.9% compared to sales of $39,493,000 from the prior year first quarter. Pre-tax loss for the quarter was $340,000 compared to a pre-tax loss of $1,056,000 for the prior year period. Kewaunee recorded a net loss of $747,000 compared to net loss of $1,345,000 for the prior year period. Margins for the current quarter were negatively impacted as the Company worked to deliver a large portion of the remaining direct orders in its order backlog. Nearly 25% of the current period’s domestic segment revenue was for direct orders that, in aggregate, were delivered at a loss for the Company. Most of these projects were tied to contracts that were executed prior to the broad-based inflation experienced last fiscal year. EBITDA1 for the quarter was $275,000 compared to ($342,000) for the prior year period. Diluted loss per share was ($0.27), as compared to diluted loss per share of ($0.48) in the prior year first quarter.
The Company’s order backlog was $174.0 million on July 31, 2022, increasing from $120.6 million on July 31, 2021, and $173.9 million on April 30, 2022. This is the fourth time in the last five quarters that the Company has recorded a record order backlog.
Domestic Segment – Domestic sales for the quarter were $37,468,000, an increase of 26.3% from sales of $29,663,000 in the prior year period. The increase in sales was predominantly from higher input costs being rolled into product pricing. Domestic segment net income was $98,000 compared to net loss of $209,000 in the prior year period. Domestic segment EBITDA was $711,000 compared to $399,000 for the prior year period.
International Segment – International sales for the quarter were $12,655,000, an increase of 28.7% from sales of $9,830,000 in the prior year period due to the commencement of delivery of large projects booked in the prior fiscal year. International segment net income was $687,000 compared to $375,000 in the prior year period. International segment EBITDA was $1,051,000 compared to $647,000 for the prior year period.
Corporate Segment – Corporate segment pre-tax net loss was $1,532,000 for the quarter, as compared to $1,511,000 in the prior year period. Corporate segment EBITDA for the quarter was ($1,487,000) compared to corporate segment EBITDA of ($1,388,000) for the prior year period. The primary driver of the change in EBITDA was higher pension expense due to the change in the underlying asset valuation for the Company’s frozen pension plan.
Total cash on hand on July 31, 2022 was $21,534,000, as compared to $6,894,000 on April 30, 2022. The increase in cash was primarily from proceeds of the sale-leaseback financing transaction that was recorded as a note receivable on April 30, 2022 and advanced billings received for several large international projects. Working capital was $48,266,000, as compared to $25,709,000 at the end of the first quarter last year and $49,272,000 on April 30, 2022. The Company had no short-term debt as of July 31, 2022, as compared to $1,588,000 on April 30, 2022. Long-term debt was $29,505,000 on July 31, 2022 as compared to $29,704,000 on April 30, 2022. The Company’s debt-to-equity ratio on July 31, 2022 was 1.09-to-1, as compared to 1.07-to-1 on April 30, 2022.
“As we announced last year, we made the strategic decision to stop direct sales in markets where the Company historically had done so, assigning these territories to two of our dealers,” said Thomas D. Hull III, Kewaunee’s President and Chief Executive Officer. “During the first quarter we delivered a large portion of our remaining direct order backlog. Many of these contracts were signed prior to the broad-based inflation experienced last year and were delivered at a loss. While we will continue to deliver the remainder of the direct order backlog over the course of the year, the financial impact is expected to diminish relative to the current quarter as the mix will continue to shift away from direct orders.”
“In the last quarter we improved the attractiveness of our backlog in two ways. First, the backlog remained at record levels. Second, our backlog margin improved as we continued to replace the low margin direct sales orders with higher margin product sales. It is our expectation that this dynamic will lead to margin expansion as we move through the fiscal year.”
“While economic uncertainty exists, from continued broad-based inflation to concern about a possible pending recession, I am optimistic about the future based on the strength of our order backlog and the continued high level of activity in the marketplace.”
|
____________________________ |
|
1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure. |
EBITDA and Segment EBITDA Reconciliation
|
Quarter Ended July 31, 2021 |
Domestic |
International |
Corporate |
Consolidated |
||||
|
Net Earnings (Loss) |
$ (209) |
$ 375 |
$ (1,511) |
$ (1,345) |
||||
|
Add/(Less): |
||||||||
|
Interest Expense |
— |
1 |
105 |
106 |
||||
|
Interest Income |
— |
(46) |
(1) |
(47) |
||||
|
Income Taxes |
— |
251 |
— |
251 |
||||
|
Depreciation and Amortization |
608 |
66 |
19 |
693 |
||||
|
EBITDA |
$ 399 |
$ 647 |
$ (1,388) |
$ (342) |
||||
|
Quarter Ended July 31, 2022 |
Domestic |
International |
Corporate |
Consolidated |
||||
|
Net Earnings (Loss) |
$ 98 |
$ 687 |
$ (1,532) |
$ (747) |
||||
|
Add/(Less): |
||||||||
|
Interest Expense |
— |
31 |
353 |
384 |
||||
|
Interest Income |
— |
(110) |
(356) |
(466) |
||||
|
Income Taxes |
— |
379 |
— |
379 |
||||
|
Depreciation and Amortization |
613 |
64 |
48 |
725 |
||||
|
EBITDA |
$ 711 |
$ 1,051 |
$ (1,487) |
$ 275 |
About Non-GAAP Measures
EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. We believe EBITDA and Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization, which can vary significantly between companies depending upon many factors. EBITDA and Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA and Segment EBITDA can vary among companies. The amounts included in the EBITDA and Segment EBITDA calculations, however, are derived from amounts included in the historical statements of operations. EBITDA and Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company’s operating performance, or as an alternative to operating cash flows as a measure of liquidity.
About Kewaunee Scientific
Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company’s products include steel, wood, and laminate casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin worksurfaces and sinks.
The Company’s corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific’s website is located at http://www.kewaunee.com.
This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe” and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: competitive and general economic conditions and the ongoing impact of the COVID-19 pandemic, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers’ required delivery schedules; risks related to fluctuations in the Company’s operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, natural disasters and other Force Majeure events; and the ultimate impact on the Company of the cyber attack suffered on November 5, 2021. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders’ interest. Many important factors that could cause such a difference are described under the caption “Risk Factors,” in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2022, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
|
Contact: |
Donald T. Gardner III |
|
704/871-3274 |
|
Kewaunee Scientific Corporation |
||||
|
Condensed Consolidated Statements of Operations |
||||
|
(Unaudited) |
||||
|
($ and shares in thousands, except per share amounts) |
||||
|
Three months ended |
||||
|
July 31, |
||||
|
2022 |
2021 |
|||
|
Net sales |
$ 50,123 |
$ 39,493 |
||
|
Cost of products sold |
43,927 |
33,819 |
||
|
Gross profit |
6,196 |
5,674 |
||
|
Operating expenses |
6,592 |
6,765 |
||
|
Operating loss |
(396) |
(1,091) |
||
|
Pension (expense) income |
(27) |
89 |
||
|
Other income, net |
467 |
52 |
||
|
Interest expense |
(384) |
(106) |
||
|
Loss before income taxes |
(340) |
(1,056) |
||
|
Income tax expense |
379 |
251 |
||
|
Net loss |
(719) |
(1,307) |
||
|
Less: net earnings attributable to the noncontrolling interest |
28 |
38 |
||
|
Net loss attributable to Kewaunee Scientific Corporation |
$ (747) |
$ (1,345) |
||
|
Net loss per share attributable to |
||||
|
Kewaunee Scientific Corporation stockholders |
||||
|
Basic |
($0.27) |
($0.48) |
||
|
Diluted |
($0.27) |
($0.48) |
||
|
Weighted average number of common shares outstanding |
||||
|
Basic |
2,807 |
2,777 |
||
|
Diluted |
2,807 |
2,777 |
||
|
Kewaunee Scientific Corporation |
||||
|
Condensed Consolidated Balance Sheets |
||||
|
($ in thousands) |
||||
|
July 31, |
April 30, |
|||
|
2022 |
2022 |
|||
|
Assets |
(Unaudited) |
|||
|
Cash and cash equivalents |
$ 14,360 |
$ 4,433 |
||
|
Restricted cash |
7,174 |
2,461 |
||
|
Receivables, less allowances |
40,714 |
41,254 |
||
|
Inventories |
25,100 |
23,796 |
||
|
Note Receivable |
– |
13,457 |
||
|
Prepaid expenses and other current assets |
10,435 |
6,164 |
||
|
Total Current Assets |
97,783 |
91,565 |
||
|
Net property, plant and equipment |
14,786 |
15,121 |
||
|
Right of use assets |
8,955 |
7,573 |
||
|
Other assets |
4,119 |
4,514 |
||
|
Total Assets |
$ 125,643 |
$ 118,773 |
||
|
Liabilities and Stockholders’ Equity |
||||
|
Short-term borrowings |
$ – |
$ 1,588 |
||
|
Current portion of lease obligations |
1,757 |
1,445 |
||
|
Current portion of financing liability |
591 |
575 |
||
|
Accounts payable |
25,042 |
27,316 |
||
|
Other current liabilities |
22,127 |
11,369 |
||
|
Total Current Liabilities |
49,517 |
42,293 |
||
|
Long-term portion of lease obligations |
7,366 |
6,407 |
||
|
Long-term portion of financing liability |
28,618 |
28,775 |
||
|
Other non-current liabilities |
4,959 |
5,118 |
||
|
Total Liabilities |
90,460 |
82,593 |
||
|
Kewaunee Scientific Corporation Equity |
34,686 |
35,694 |
||
|
Non-controlling interest |
497 |
486 |
||
|
Total Stockholders’ Equity |
35,183 |
36,180 |
||
|
Total Liabilities and Stockholders’ Equity |
$ 125,643 |
$ 118,773 |
||
View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-first-quarter-of-fiscal-year-2023-301620880.html
SOURCE Kewaunee Scientific Corporation
